Wanted pages

From Glioblastoma Treatments
Jump to navigationJump to search

List of non-existing pages with the most links to them, excluding pages which only have redirects linking to them. For a list of non-existent pages that have redirects linking to them, see the list of broken redirects.

Showing below up to 50 results in range #151 to #200.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. Approved; ongoing Phase III trials for other tumor types‏‎ (1 link)
  2. Approved; ongoing trials exploring new combinations‏‎ (1 link)
  3. At higher doses: delirium and peripheral motor neuropathy; minimal toxicity when alcohol is not consumed‏‎ (1 link)
  4. BCNU alone: median survival of 11 months‏‎ (1 link)
  5. Blood clots, increased risk of uterine cancer in women, impotence and loss of libido in men, weight gain‏‎ (1 link)
  6. COC Protocol (Care Oncology Clinic Protocol)‏‎ (1 link)
  7. Carefully monitored to avoid clinical symptoms of hypothyroidism; includes potential for fatigue if not properly managed‏‎ (1 link)
  8. Chloroquine with BCNU: median survival significantly improved to 25-33 months; recent meta-analysis supports decreased mortality and improved survival time in glioblastoma patients‏‎ (1 link)
  9. Clinical trials (e.g., advanced cancer study with cachexia, metastatic breast cancer Phase II trial, advanced non-small cell lung cancer trial)‏‎ (1 link)
  10. Clinical use with retrospective analysis; some components in clinical trials for cancer‏‎ (1 link)
  11. Clinics‏‎ (1 link)
  12. Common PPI side effects include headache, nausea, diarrhea, abdominal pain, fatigue, and dizziness‏‎ (1 link)
  13. Common side effects associated with Keppra include fatigue, dizziness, and mood changes, but it is generally well-tolerated in the context of brain tumor treatment.‏‎ (1 link)
  14. Data on progression-free survival specifically for SL-701 is under investigation; significant antitumor activity has been noted.‏‎ (1 link)
  15. Data suggests tamoxifen may extend survival for certain glioblastoma patients, with specific outcomes depending on the study and patient demographics‏‎ (1 link)
  16. Deep vein thrombosis, peripheral neuropathy, constipation, somnolence, pyrexia, pain, teratogenicity‏‎ (1 link)
  17. Dose-intense temozolomide alone: Median survival from trial start was 369 days (12.1 months)‏‎ (1 link)
  18. Dry skin, liver problems, increased blood lipid levels, dry mouth, muscle or joint pain, sun sensitivity‏‎ (1 link)
  19. EGFR Inhibitors (Tarceva, Erbitux) in combination with Stupp Protocol‏‎ (1 link)
  20. Early-stage clinical trials, including studies in Brazil for recurrent glioma‏‎ (1 link)
  21. Early clinical trials and case studies, including a phase 2 clinical trial in Israel (NCT02654041)‏‎ (1 link)
  22. Early clinical trials and observational studies, including phase 2 trials combining Celebrex with conventional cancer treatments‏‎ (1 link)
  23. Early phase trials‏‎ (1 link)
  24. Early results suggest potential efficacy in enhancing chemotherapy response; ongoing trials‏‎ (1 link)
  25. Early to mid-stage clinical trials‏‎ (1 link)
  26. Evidence from colorectal cancer trials shows increased disease-free survival‏‎ (1 link)
  27. Exploratory/Investigational (Specific phase for gliomas not provided)‏‎ (1 link)
  28. Exploratory and Phase 1/2 trials for recurrent glioma in combination with other agents‏‎ (1 link)
  29. Extended survival reported in some clinical trials‏‎ (1 link)
  30. Eye toxicities, especially blurred vision‏‎ (1 link)
  31. Fatigue, injection site reaction, erythema, and pain were the most common treatment-related adverse events. No grade 4/5 adverse events reported, indicating a manageable safety profile.‏‎ (1 link)
  32. Fevers, altered mental status shortly after infusion, significant but manageable neurotoxicity‏‎ (1 link)
  33. Few reported; mainly gastrointestinal disturbances‏‎ (1 link)
  34. Gastro-intestinal side effects when administered orally; intranasal administration used to mitigate this‏‎ (1 link)
  35. Gastrointestinal upset, such as diarrhea and nausea; lactic acidosis (rare but serious)‏‎ (1 link)
  36. Generally well-tolerated; bioavailability issues are noted, but can be improved with piperine‏‎ (1 link)
  37. Generally well-tolerated; known side effects include gastrointestinal discomfort and a strong odor. Rare cases of allergic reactions.‏‎ (1 link)
  38. Generally well-tolerated; possible digestive disturbances at high doses‏‎ (1 link)
  39. Generally well-tolerated; possible mild gastrointestinal issues and fatigue. No unexpected adverse effects in clinical trials.‏‎ (1 link)
  40. Generally well-tolerated; potential gastrointestinal issues with long-term use of some NSAIDs. Celebrex designed to minimize COX-1 inhibition and related stomach issues.‏‎ (1 link)
  41. Generally well-tolerated; some reports of gastrointestinal disturbances at high doses‏‎ (1 link)
  42. Generally well-tolerated; specific studies noted minimal impact on adverse event incidence‏‎ (1 link)
  43. Hematologic, gastrointestinal, and hepatic toxicities noted; acceptable safety profile in combination regimens‏‎ (1 link)
  44. Hematological toxicity, nausea, vomiting, and pulmonary toxicity‏‎ (1 link)
  45. Hepatic and pulmonary toxicity, myelosuppression‏‎ (1 link)
  46. Higher rates of thrombocytopenia, neutropenia, and anemia were observed in some studies‏‎ (1 link)
  47. Historical controls indicate median overall survival around 15-17 months for newly diagnosed GBM.‏‎ (1 link)
  48. Historical controls suggest a median overall survival of 20-35% at 12 months for similar populations.‏‎ (1 link)
  49. Historical controls suggest a median survival time of 6 months for recurrent GBM‏‎ (1 link)
  50. Hot flashes, joint pain, nausea, increased risk of osteoporosis, fatigue‏‎ (1 link)

View ( | ) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Special:WantedPages"